

Biographical Sketch

Anthony W. Tolcher, M.D., FRCP(C)

Dr. Anthony W. Tolcher is the Director of Clinical Research at START (South Texas Accelerated Research Therapeutics) in San Antonio, Texas.

He is a graduate of the University of British Columbia in Vancouver, Canada. He performed his residency in internal medicine at the University of Toronto and his fellowship in oncology at the University of British Columbia. He followed this with a research fellowship at the National Cancer Institute, Bethesda, Maryland. Dr. Tolcher was the Director of Clinical Research at the Cancer Therapy and Research Center (CTRC) in San Antonio from 2003 until April, 2007, and prior to that served as the Associate Director at the CTRC from 1999 to 2003.

Dr. Tolcher's major interest is in the development of new anticancer agents, with a special interest in molecular genetic targets for cancer therapy.

He was a Fogarty Fellow at the National Institute of Health, and received the Murray Muirhead Award for humanitarian and academic excellence, and the Goel Prize in Medicine for excellence in the Clinical Disciplines.

He is a Fellow of the Royal College of Physicians of Canada; a Diplomate of the American Board of Internal Medicine and Medical Oncology; a Fellow of the American College of Physicians, and a member of the American Association for Cancer Research, the American Society of Clinical Oncologists, and the European Society for Medical Oncology. He also serves as a member of the American Society of Clinical Oncology Scientific Program Committee and the Cancer Education Committee.

He is an Associate Editor of the The Journal of New Anticancer Agents; and he is a scientific grant reviewer for the National Cancer Institute of Canada. Dr. Tolcher has authored numerous publications, including 89 peer reviewed publications, 143 Conference Proceedings, and 9 book chapters. He serves as a reviewer for the following journals: Anti-Cancer Drugs, Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research, Clinical Lung Cancer, Clinical Prostate Cancer, Human Gene Therapy, and the Journal of Cancer.